(Q45408093)

14 December 2017

Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses (English)

1 reference

Venezuelan equine encephalitis

14 December 2017

1 reference

1 reference

based on heuristic

inferred from title

Venezuelan equine encephalitis virus

object named as

Venezuelan equine encephalitis virus

1 reference

8

Ann M Powers

1 reference

14 December 2017

9

Richard A Bowen

1 reference

14 December 2017

Donald L Fine

1

1 reference

14 December 2017

Brian A Roberts

2

1 reference

14 December 2017

Max L Teehee

3

1 reference

14 December 2017

Sara J Terpening

4

1 reference

14 December 2017

Cindy L H Kelly

5

1 reference

14 December 2017

Janae L Raetz

6

1 reference

14 December 2017

Dale C Baker

7

1 reference

14 December 2017

language of work or name

English

0 references

publication date

27 October 2006

1 reference

14 December 2017

1 reference

14 December 2017

25

1 reference

14 December 2017

10

1 reference

14 December 2017

1868-1876

1 reference

Venezuelan equine encephalitis

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Antigenic variants of Venezuelan equine encephalitis virus: their geographic distribution and epidemiologic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Enzootic and Epizootic Venezuelan Equine Encephalomyelitis Virus in Horses Infected by Peripheral and Intrathecal Routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Venezuelan Equine encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.10.030

1 reference

14 December 2017

1 reference